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The discovery of the adipocyte hormone leptin completely changed our view
of energy metabolism. In addition, the discovery of leptin rapidly progressed
to clinical development. After a decade of clinical studies, leptin appears not
to be the magic bullet therapy for obesity; however, it has a robust role in rare
human conditions characterized by its deficiency. Recent exciting work from
the Unger laboratory suggests that leptin therapy may also have a potential
role for the treatment of Type 1 diabetes. In this review we discuss the positive
evidence why such an approach is worthwhile. In order to achieve this broad
goal, we reviewed available literature and provided our interpretation of the
evidence presented in the original research papers. The potential cautionary
aspects of this novel approach will be discussed in an accompanying article.
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Exactly 72 years after the discovery of insulin, a
hormone that offered life full of potential to all
paitents with type 1 diabetes, an equally groundbreak-
ing discovery of the adipocytokine, leptin, completely
changed our understanding of energy homeostasis in
mammals. This pivotal discovery has granted a new
status to adipose tissue as an endocrine organ, pro-
moted the central nervous system to the level of master
regulator of human metabolism, and quickly led to
the development of leptin analogs as potential human
therapies. Although the original focus was exploration
of leptin as a potential therapy for human obesity,
both animal and clinical data in multiple disease states
provide strong support for a leptin analog as a potent
physiological replacement therapy in states of ‘leptin
deficiency’. While trying to understand the therapeu-
tic roles for leptin, two important facts need to be
kept in mind: (i) leptin is a pleiotropic hormone with
many regulatory functions and (ii) the clinical applica-
bility of leptin is likely wider than absolute deficiency.
Anchoring onto these facts, novel therapeutic poten-
tials for leptin are being sought in other disease states.
Among these, type 1 diabetes stands out as an area for
which there is a lot of enthusiasm, leading to excit-
ing, newly piloted human trials, which comprise the
translational extension of a recently published study
by Wang and Unger (1). The purpose of this article is
to summarize the basic and clinical data that provide
support to exploration of leptin as an adjunctive ther-
apy for patients suffering from type 1 diabetes. I will
also present our vision of how leptin therapy may be
utilized in the clinical setting of type 1 diabetes. Clearly,
far more data are needed to define the precise role of
this remarkable hormone as therapy in type 1 diabetes.
A brief review of leptin physiology
Since the story of leptin therapeutics begins with the
discovery of leptin, it is useful to briefly review the
physiology of leptin. A protein structurally similar to
cytokines, leptin is the protein product of the ob gene in
mice and humans (2). The main site of leptin synthesis
is adipose tissue (white more than brown, subcutaneous
more than visceral) and blood levels of leptin correlate
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with total body fat. Leptin’s main function is thought
to be as an energy sensor via informing the brain
of the energy storage level of the body (3). In
response to this signal, the brain makes appropriate
adjustments to change food intake and energy
expenditure to re-establish the energy homeostasis. The
ob/ob mice, which have complete deficiency of leptin,
are hyperphagic, hypothermic, and morbidly obese,
indicating increased energy intake with reduced energy
expenditure (3). Treating ob/ob mice with leptin causes
a decrease in appetite and promotes weight loss, the
majority of which is the total body fat. These mice also
have a marked hepatic steatosis coupled with hepatic
insulin resistance and hyperglycemia. In addition, the
ob/ob mice are infertile and have a number of other
hypothalamic pituitary axes abnormalities such as
central hypothyroidism, hypercorticosteroenemia due
to central corticotropin releasing factor (CRF) neuron
activation, and central linear growth impairment.
More recently, immunological abnormalities such
as decreased CD4 counts, impaired activation of
peripheral blood mononuclear cells and a protective
effect against permissive autoimmunity have been
observed in the murine ob/ob model. Replacement
of leptin in the ob/ob mouse significantly reverses
or corrects all these abnormalities. As such, leptin is
viewed now not as a simple signal that mediates eating
behavior, but rather an integrative control switch,
signaling status of energy stores to the brain over a
period of days to weeks that in turn controls adaptive
response to a state of low energy availability.
Why leptin therapy may have theraputic
potential in type 1 diabetes
We have come up with what we believe are the ‘Top
10’ reasons why leptin therapy may have therapeutic
potential in type 1 diabetes in Table 1. It is important
to note that we do not foresee that leptin therapy would
replace insulin treatment completely. Rather, we fore-
see a role for leptin as an adjunctive therapy to help
‘fine-tune’ metabolic control. It could be administered
to reduce the number of insulin injections as well as the
total daily dose required. It could help smooth out the
variability in postmeal excursions as wellas reducing
basal insulin doses required to decrease hepatic glucose
output. Now that we have provided a list of reasons
why leptin therapy may be of benefit in type 1 diabetes
and offered a context for its use, let us examine each
point closely.
The need for improved therapy in type 1 diabetes
Type 1 diabetes affects 0.5% of the general population.
Even though we have come a long way in the delivery of
insulin analogs to patients, current treatment strategies
Table 1. Top 10 reasons why leptin may have a therapeutic
role in type 1 diabetes
S.No Reasons
1 There is an ongoing need to improve the treatment
plan of type 1 diabetics. New drugs are needed.
2 Type 1 diabetes is a state of ‘relative leptin
deficiency’. Replacement of leptin in states of
leptin deficiency is effective.
3 Leptin has antisteatotic actions in peripheral
tissues. Steatosis, which can be promoted by
insulin therapy, is known to predict and may
even cause cardiovascular death.
4 Leptin can suppress elevated glucagon levels.
Targeting just elevated glucagon levels can
abrogate the need for insulin in rodents.
5 Leptin can lead to the restoration of insulin
secretion in islets by reversing lipotoxicity.
6 Leptin can reduce food intake in non-obese
humans and can oppose insulin-induced weight
gain in rodent models.
7 Leptin can improve lipid metabolism in ways that
insulin cannot.
8 Leptin improves insulin sensitivity in human
lipodystrophy.
9 Leptin ameliorates metabolic control in patients
with autoimmune lipodystrophy and type 1
diabetes without adverse clinical effects on the
course of the background autoimmune disorder.
10 Leptin can ameliorate metabolic control in patients
with presumed insulin receptor mutations
carrying the clinical diagnosis of Rabson–
Mendenhall syndrome. Thus, leptin can crosstalk
with insulin-signaling cascade in humans.
are cumbersome and the majority of patients fall short
of desired metabolic control. Even with metabolic con-
trol at its best, patients still experience a high variability
of glucose levels especially after meals. Patients are con-
stantly threatened by fear of hypoglycemia and weight
gain even with near-goal hemoglobin A1c (HbA1c) lev-
els. These latter two conditions continue to contribute
to reduced life expectancy in type 1 diabetes as well
as reduced quality of life. Current rapid acting insulin
analogs peak their action within 2 h and work for about
4 h. The normal pancreas on the other hand is capa-
ble of responding to a meal challenge by rapid insulin
release and getting it cleared by 50% within 5 min. The
delayed onset of subcutaneously injected insulin results
in immediate postmeal glucose excursions followed by
a rapid drop in blood glucose as insulin becomes avail-
able. Any delayed effect of food on glycemia caused by
the ingestion of lipids or amino acids are typically not
accounted for by meal bolus dosing.
Another imperfection in current insulin-dosing reg-
imens results from the discordance between sensitivity
thresholds in insulin signaling to regulate lipogenesis
vs. gluconeogenesis in the liver. The basal doses of
insulin typically used in clinical practice are still able
to promote lipogenesis, while raising the threshold for
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regulation for hepatic glucose output. Understanding
this paradox would help understand why weight gain
can occur while diabetes is still poorly controlled and
why weight gain almost always accompanies improved
glucose control. In search of bettering glycemic con-
trol, novel hormonal therapies for type 1 diabetes have
emerged such as amylin analogs. One presumed action
of the amylin hormone is targeting glucagon over-
secretion that is known to be a key metabolic feature
of insulin deficiency. Therefore, other additional ther-
apeutic targets such as leptin (see evidence below) that
affect glucagon oversecretion or which alter postmeal
lipid or amino-acid handling may have a place in more
modern type 1 diabetes regimens. Furthermore, leptin
can simply reduce food intake and thus create an effect
by reducing the ‘meal-burden’ and providing a net
positive effect on glycemic control.
Type 1 diabetes: a state of ‘relative insulin
deficiency’
The real success of leptin therapy has been observed
in the adaptation of hormone replacement strategy
in states of leptin deficiency because low leptin lev-
els appear to provide an integrative signal of energy
deficit for the organism. Reduced food availability and
empty adipocyte stores lead to the low leptin signal.
Insulin deficiency in type 1 diabetes causes a state of
increased lipolysis from the adipocytes which increases
circulating free fatty acids and eventually ketonemia.
Both these metabolites can reduce adipocyte’s ability
to secrete leptin, signaling an ‘energy deficit’. There-
fore, type 1 diabetes is one of the conditions that we
have begun to call ‘relative leptin deficiency’ to begin to
describe conditions which may be amenable to leptin
repletion strategy. Aside from type 1 diabetes, sleep
deprivation, Circadian shifts, hypothalamic amenor-
rhea, genetic mechanisms that interfere with leptin
secretion, and variations in body fat depots such as par-
tial lipodystrophy syndromes or loss of subcutaneous
fat compartments are among other conditions charac-
terized by ‘relative leptin deficiency’. In our opinion,
the repletion strategy to be used in the treatment of
relative leptin deficiency is analogous to the recently
published experience from heterozygote ob mice (4).
Leptin has strong antisteatotic effects
Steatosis is the deposition of lipids inside tissues outside
the adipose tissue. It usually occurs due to the availabil-
ity of excess lipids for storage above and beyond what
the adipose compartment can store. Thus, steatosis is
a complication of obesity, but is also seen as a result
of lipodystrophy (a human condition characterized by
a paucity of fat either through acquired or genetic
reasons). Insulin can promote steatosis in the liver and
is a long-term complication of insulin therapy. From a
therapeutic perspective, it is important to try to target
steatosis because the presence of fat in the muscle and
liver is associated with an increased risk of cardiovas-
cular disease. Hepatic steatosis is now regarded as at
least a forecaster of future cardiovascular events and
may even play a causative role.
Leptin replacement strategy leads to resolution
of steatosis in the liver and muscle of both ob/ob
mice as well as multiple models of leptin-deficient
lipodystrophy. Similarly, humans with lipodystrophy
respond to leptin therapy with a remarkable resolution
of steatosis both in the liver and in muscle. In a
mouse model of lipodystrophy, resolution of steatosis
in response to physiological leptin replacement was
evident after 3 weeks of therapy (5). Furthermore, this
study showed that lipogenesis was dysregulated in the
liver in the absence of leptin, which was corrected
with leptin replacement. To elucidate the mechanism
by which leptin reduces hepatic lipid content in livers,
Cohen et al. used microarrays to identify genes in the
liver that were differentially regulated by leptin or
by food restriction (pair-feeding). The gene encoding
stearoyl-CoA desaturase (SCD-1) ranked the highest
in this analysis (6). The microsomal enzyme SCD-1 is
required for the biosynthesis of the monounsaturated
fats palmitoleate and oleate from saturated fatty acids.
Additionally, leptin increases hepatic and adipocyte
expression of PPAR-α coactivator-1α (7) which
regulates mitochondria biogenesis and fat oxidation.
Another important antisteatotic effect of leptin was
uncovered by studying muscle tissue. Minokoshi and
colleagues showed that leptin selectively stimulates
phosphorylation and activation of the α2 catalytic sub-
unit of AMPK in skeletal muscle, thus establishing a
previously unknown signaling pathway for leptin (8).
In parallel with its activation of AMPK, leptin sup-
presses the activity of acetyl-CoA carboxylase, thereby
stimulating the oxidation of fatty acids in muscle.
These antistetaotic effects of leptin which are periph-
eral endpoints are likely mediated via its central action
and not directly through its peripheral receptors. The
lipopenic action of leptin has been duplicated in rodents
with small, centrally administered doses (9). The effect
is achieved even with the knockout of peripheral lep-
tin receptors (10) and this suggests that leptin signals
through one or more centrally mediated intermediates,
which in turn lead to increased fatty acid oxidation and
suppression of lipogenesis.
Leptin can suppress glucagon levels and
hyperglucagonemia is a hallmark feature of type 1
diabetes
Studies emerging from the laboratory of Roger
Unger over the last 35 years have suggested that
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hyperglucagonemia is a key characteristic of the
diabetic state and the hepatic actions of glucagon after
meals to stimulate hepatic glucose output accounted
for most of the postmeal excursions in glucose levels. As
shown in the paper by Wang and Unger in 2010, leptin
therapy reversed the diabetic state of multiple models
of insulin deficiency and abrogated the need for insulin
therapy (1). The authors have suggested that these
actions of leptin were related to a reduction in plasma
glucagon levels. More recently, the same laboratory has
published that glucagon receptor-deficient mice treated
with streptozotocin (STZ) did not develop a need for
insulin therapy despite losing insulin secretion (11).
These results were supported in a study by Hancock
et al. that mice, lacking alpha cells, were also protected
from clinical diabetes despite STZ treatment and loss of
insulin secretion (12). Such observations led the Unger
lab to posit that insulin would have no role in a liver not
exposed to the action of glucagon and leptin appeared
to be one of the key regulators of glucagon secretion.
Leptin reduces food intake in non-obese humans
and opposes insulin-induced weight gain observed
in models of type 1 diabetes
Leptin therapy leads to a reduction in food intake in
non-obese humans such as women with hypothala-
mic amenorrhea (13) and in patients with lipodystro-
phy (14) as well as a few obese humans with mutations
in the leptin gene (15). This is usually in parallel to a
reduction in body weight, with predominant fat loss as
opposed to lean mass. A similar effect was observed
in obese humans who were treated with leptin alone
or in combination with Pramlintide (16). Thus, leptin
would be expected to lower food intake and decrease
the overall meal load. Historically, prior to the dis-
covery of insulin, the treatment for type 1 diabetes
was caloric restriction and forced starvation. Leptin
therapy may in some ways simulate such a state by sig-
naling a decreased need for food (i.e., Being ‘content’),
reducing the need for insulin.
In the leptin-treated mouse models of type 1
diabetes, limitation of food intake by pair-feeding
animals without leptin administration did not provide
the extent of benefit noted on glucose and lipid
parameters, and liver weight, suggesting that leptin’s
effect on metabolism is not totally dependent on
limiting food intake (1). As expected, leptin therapy
led to a decrease in body weight primarily from the
body fat compartment but also lowered hepatic fat
depots, while insulin therapy led to an increase in body
weight as well as an increase in hepatic fat content.
Leptin has unique effects on lipid metabolism
In the above sections, we have touched upon distinctive
effects of leptin on lipid metabolism. Leptin reverses
steatosis uniquely. It promotes beta-oxidation of fatty
acids in both muscle and liver. It can also have
consequences in the adipose tissue either directly or
through lowering glucagon, to switch the metabolic
pathways toward oxidation and inhibiting lipogenesis.
Leptin has a regulatory action on key transcriptional
factors such as steroid regulatory element binding
protein 1 (SREBP1) and SCD1 as well as PPAR-α.
Unger and Wang have also demonstrated an improved
cholesterol profile of diabetic mice upon treatment
with leptin (1). Leptin also lowers triglyceride levels
in this setting as well as in rodents and humans
with lipodystrophy.The vast amount of available data
in the literature underscores that leptin and insulin
have parallel central nervous system effects to regulate
glucose metabolism and food intake, while their effects
on lipid metabolism are distinctive.
Leptin can lead to restoration of insulin secretion
by opposing ‘lipotoxic’ effects on islet cells
From 1995 to 2002, the Unger laboratory focused
their efforts in defining the phenomenon of lipotoxic-
ity (17). This is a term to describe the consequences of
lipid spillover to tissues outside the adipocytes such as
liver, muscle, myocardium, and islets. Accumulation
of excessive lipid in the islets were reported to cause
ceramide accumulation, increased fibrosis, and apop-
tosis. Restoration of leptin signaling or leptin repletion
successfully recovered islet cell insulin secretion and
reversed diabetes in multiple rodent models of obesity,
leptin resistance, or leptin deficiency (17). These find-
ings add to the characteristics of leptin that make it an
attractive tool for the treatment of type 1 diabetes.
Leptin works as an insulin-sensitizer in vivo
in some human conditions characterized
by leptin-deficiency such as severe lipodystrophy
In 2000, about 6 years after the discovery of leptin, we
began the first leptin replacement trial in patients with
severe lipodystrophy (14). The goal of these studies was
physiologic replacement, analogous to using insulin
in type 1 diabetes, because in both disease states the
organs that manufactures the replaced hormone are
functionally absent. In a short period such as a few
months, patients with the most severe forms of fat
deficiency and most pronounced metabolic defects
showed a remarkable improvement in their insulin
sensitivity and dyslipidemia. An average of 1.5–2%
reduction in HbA1c has remained constant at 4-
and 12-month time points after initiation of leptin
throughout a decade of ongoing studies (18). The
improvement in insulin sensitivity was apparent in
liver as well as in muscle compartments. These studies
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demonstrated for the first time that leptin had insulin-
sensitizing actions in humans and that leptin accounted
for most of the metabolic effects of adipose tissue.
Leptin enhances metabolic control in humans with
autoimmune lipodystrophy and type 1 diabetes
Among lipodystrophic patients who were treated
with leptin, there were at least three patients who
had clear evidence for autoimmune lipodystophy and
type 1 diabetes ((19) and unpublished observations).
In these selected patients, it is reassuring that leptin
led to significant metabolic improvements such as
reductions in HbA1c, triglycerides, food intake (also
with reduction in anxiety associated with constantly
seeking food), and improvement in hepatic steatosis.
None of the patients experienced deterioration in
their underlying autoimmune diseases. It is also
important to point out that none of these patients were
able to discontinue insulin therapy completely, but
their insulin dosages were reduced from heroic doses
down to weight-consistent ranges. They were able to
reduce the number of insulin injections required to
maintain normoglycemia. All three patients expressed
satisfaction with their regimen and attributed the
satisfaction to reduction in hepatomegaly (which was
impeding their mobility) as well as improved satiety.
Leptin helps to improve metabolic control in
patients with presumed insulin receptor mutations
We also had the opportunity to treat and observe
the metabolic effects caused by leptin therapy in two
siblings who had the clinical features of Rabson–
Mendenhall syndrome with severe hyperinsulinemia,
acanthosis nigricans, hyperglycemia, short stature,
and multiple dysmorphic features (20). These patients
(even though not studied) have presumed mutations
of their insulin receptor gene. They also displayed
relatively low levels of circulating leptin (3–4 ng/dL)
and thus were treated with recombinant leptin now for
nearly 10 years. In both these patients, leptin therapy
helped to decrease insulin doses and improve glucose
control, decreasing glucosuria and allowing improved
growth. Leptin therapy was withdrawn in a controlled
setting on two separate occasions over the observation
period and both these periods were associated with
worsening metabolic control and a dramatic increase
in insulin dosages. The effects observed in these two
patients comprise the most direct evidence that insulin
and leptin signaling crosstalk to regulate glucose
metabolism in humans.
Conclusions
In conclusion, the available preclinical evidence studied
mostly in the Unger laboratory over a 15-year-time
period coupled with results available from the
translational studies obtained in humans with various
forms of leptin deficiency and diabetes, support the
notion that it is worthwhile to undertake clinical trials
to test the effects of leptin in patients with type 1
diabetes. As mentioned previously and as suggested by
our limited experience in patients with type 1 diabetes
and acquired lipodystrophy, we do not foresee that
leptin can replace insulin therapy in type 1 diabetes. It
can, however, have a strong adjunctive role. As human
studies are being undertaken, certain areas of caution
(which are mentioned in an accompanying paper) will
have to be carefully weighed and incorporated into the
study design with appropriate safety measures.
References
1. Wang MY, Chen L, Clark GO et al. Leptin therapy
in insulin-deficient type I diabetes. Proc Natl Acad Sci
U S A 2010: 107: 4813–4819.
2. Zhang Y, Proenca R, Maffei M, Barone M,
Leopold L, Friedman JM. Positional cloning of the
mouse obese gene and its human homologue. Nature
1994: 372: 425–432.
3. Friedman JM,Halaas JL. Leptin and the regulation of
body weight in mammals. Nature 1998: 395: 763–770.
4. Begriche K, Letteron P, Abbey-Toby A et al. Partial
leptin deficiency favors diet-induced obesity and related
metabolic disorders in mice. Am J Physiol Endocrinol
Metab 2008: 294: E939–E951.
5. Shimomura I, Hammer RE, Ikemoto S, Brown MS,
Goldstein JL. Leptin reverses insulin resistance and
diabetes mellitus in mice with congenital lipodystrophy.
Nature 1999: 401: 73–76.
6. Cohen P, Miyazaki M, Socci ND et al. Role for
stearoyl-CoA desaturase-1 in leptin-mediated weight
loss. Science 2002: 297: 240–243.
7. Puigserver P, Spiegelman BM. Peroxisome pro-
liferator-activated receptor-gamma coactivator 1 alpha
(PGC-1 alpha): transcriptional coactivator and
metabolic regulator. Endocr Rev 2003: 24: 78–90.
8. Minokoshi Y, Kim YB, Peroni OD et al. Leptin
stimulates fatty-acid oxidation by activating AMP-
activated protein kinase. Nature 2002: 415: 339–343.
9. Asilmaz E, Cohen P, Miyazaki M et al. Site and
mechanism of leptin action in a rodent form of
congenital lipodystrophy. J Clin Invest 2004: 113:
414–424.
10. Cohen P, Zhao C, Cai X et al. Selective deletion of
leptin receptor in neurons leads to obesity. J Clin Invest
2001: 108: 1113–1121.
11. Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH.
Glucagon receptor knockout prevents insulin-deficient
type 1 diabetes in mice. Diabetes 2011: 60: 391–397.
12. Hancock AS, Du A, Liu J, Miller M, May CL.
Glucagon deficiency reduces hepatic glucose production
and improves glucose tolerance in adult mice. Mol
Endocrinol 2010: 24: 1605–1614.
13. Welt CK, Chan JL, Bullen J et al. Recombinant
human leptin in women with hypothalamic amenorrhea.
N Engl J Med 2004: 351: 987–997.
72 Pediatric Diabetes 2012: 13: 68–73
Leptin for type 1 diabetes: pro
14. Oral EA, Simha V, Ruiz E et al. Leptin-replacement
therapy for lipodystrophy. N Engl J Med 2002: 346:
570–578.
15. Farooqi IS, Matarese G, Lord GM et al. Beneficial
effects of leptin on obesity, T cell hyporesponsiveness,
and neuroendocrine/metabolic dysfunction of human
congenital leptin deficiency. J Clin Invest 2002: 110:
1093–1103.
16. Ravussin E, Smith SR, Mitchell JA et al. Enhanced
weight loss with pramlintide/metreleptin: an integrated
neurohormonal approach to obesity pharmacotherapy.
Obesity (Silver Spring) 2009: 17: 1736–1743.
17. Unger RH. The physiology of cellular liporegulation.
Annu Rev Physiol 2003: 65: 333–347.
18. Oral EA, Chan JL. Rationale for leptin-replacement
therapy for severe lipodystrophy. Endocr Pract 2010:
16: 324–333.
19. Park JY, Chong AY, Cochran EK et al. Type 1 dia-
betes associated with acquired generalized lipodystro-
phy and insulin resistance: the effect of long-term leptin
therapy. J Clin Endocrinol Metab 2008: 93: 26–31.
20. Cochran E, Young JR, Sebring N, DePaoli A, Oral
EA, Gorden P. Efficacy of recombinant methionyl
human leptin therapy for the extreme insulin
resistance of the Rabson-Mendenhall syndrome. J Clin
Endocrinol Metab 2004: 89: 1548–1554.
Pediatric Diabetes 2012: 13: 68–73 73
